Clinical Trials Logo

Clinical Trial Summary

The objective of our study is to evaluate the functional and morphological imaging variations at 24 and 52 weeks compared to baseline during TCZ-treatment and 6 months after the suspension of TCZ. We will also evaluate the variations of aortic dilatation during the study period using the PET/CT in comparison with an hystorical cohort of patients with LVV treated with GCs only and longitudinally followed at our rheumatology division.


Clinical Trial Description

1. Trial Design Monocentric observational study, single arm, based on imaging of patients with active Large Vessel Giant Cell Arteritis (LV-GCA) , treated with Tocilizumab (TCZ) s.c. and with ultra-short glucocorticosteroids (GCs). 2. Duration of study per Subject 52 weeks of observation during standard of care (SOC) and 24 weeks of follow-up 3. Target Population Patients aged older than 50 years with active large vessel giant cell arteritis (LV-GCA) based on evidence of large vasculitis at imaging. Patients with active disease will be enrolled according to the following inclusion criteria: - PET/CT showing vascular FDG uptake ≥2 in at least one vascular district and at least one among - ESR >40 mm/h or CRP >10 mg/l - Cranial or systemic symptoms of GCA or symptoms of polymyalgia rheumatica (PMR) 4. Primary Objectives - To evaluate the functional and morphological imaging (PET and MRA scores) variations at 24, 52 and 76 weeks compared to baseline values. - To evaluate the proportion of patients with relapse free remission (RFR) at week 24, 52 and 76. - To assess agreement between of MRA and PET scores and physician-determined disease activity status. 5. Secondary Objectives - To evaluate if patients have a reduced risk of aortic dilatation compared with an hystorical cohort of patients with LVV treated with GCs only and longitudinally followed at our rheumatology division. - immunological effects of steroid and TCZ at baseline, after 3 days, at week 24, 52 and 76 ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05394909
Study type Observational
Source Azienda Unità Sanitaria Locale Reggio Emilia
Contact
Status Active, not recruiting
Phase
Start date February 7, 2020
Completion date November 15, 2022

See also
  Status Clinical Trial Phase
Completed NCT03007186 - Glucose Monitoring During Threatening Preterm Birth in Patients With and Without Gestational Diabetes Mellitus
Not yet recruiting NCT05598411 - CST1-Guided Oral Glucocorticoids Management for CRSwNP Phase 4
Recruiting NCT05522465 - Short-course High-dose Prednisone and Dexamethasone in Children With ITP Phase 4
Recruiting NCT05598424 - CST1 Predictive Model of Oral Glucocorticoid Therapy Sensitivity for Chronic Rhinosinusitis With Polyps Phase 4
Completed NCT03125941 - High vs Low Dose Dexamethasone on Complications in the Immediate Postoperative Phase After Mastectomy Phase 4
Not yet recruiting NCT03804723 - Glucocorticoids Withdrawal in Early Systemic Lupus Erythematosus N/A
Recruiting NCT04094298 - Use of Extended Release Triamcinolone in the Treatment of Rotator Cuff Disease Phase 3
Recruiting NCT04574232 - SporTRIA Study: A Multicentre Trial for Excretion Kinetics of Triamcinolone Acetonide Following Sport Related Intra-articular Injections in Knees; Definitions of the Washout Periods N/A
Completed NCT02857842 - Corticosteroid Reduction in COPD Phase 4
Enrolling by invitation NCT05506033 - Optimization of Glucocorticoid Taper Strategies for SLE-ITP N/A